| Assessment Status | Rapid Review Complete |
| HTA ID | 26022 |
| Drug | Toripalimab |
| Brand | Loqtorzi® |
| Indication | Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 12/05/2026 |
| Rapid review completed | 09/06/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of toripalimab (Loqtorzi®) compared with the current standard of care. |